Nevertheless, one of the disadvantages of BRAF inhibitors is that they are specifically effective in tumors with mutated BRAF such as melanomas, since in those with BRAFwt, a “paradoxical activation” of ERK signaling may occur due to the drug-mediated transactivation of RAF dimers that in turn can induce other types of cancers, mainly skin cancers. The gene discussed is BRAF; the disease is skin neoplasm.